IL-22 has been identified as a cancer-promoting cytokine that is secreted by infiltrating immune cells in several cancer models. We hypothesized that IL-22 regulation would occur at the interface between cancer cells and immune cells. Breast and lung cancer cells of murine and human origin induced IL-22 production from memory CD4 + T cells. In the present study, we found that IL-22 production in humans is dependent on activation of the NLRP3 inflammasome with the subsequent release of IL-1β from both myeloid and T cells. IL-1 receptor signaling via the transcription factors AhR and RORγt in T cells was necessary and sufficient for IL-22 production. In these settings, IL-1 induced IL-22 production from a mixed T helper cell population comprised of Th1, Th17, and Th22 cells, which was abrogated by the addition of anakinra. We confirmed these findings in vitro and in vivo in two murine tumor models, in primary human breast and lung cancer cells, and in deposited expression data. Relevant to ongoing clinical trials in breast cancer, we demonstrate here that the IL-1 receptor antagonist anakinra abrogates IL-22 production and reduces tumor growth in a murine breast cancer model. Thus, we describe here a previously unrecognized mechanism by which cancer cells induce IL-22 production from memory CD4 + T cells via activation of the NLRP3 inflammasome and the release of IL-1β to promote tumor growth. These findings may provide the basis for therapeutic interventions that affect IL-22 production by targeting IL-1 activity.
IL-22 has been identified as a cancer-promoting cytokine that is secreted by infiltrating immune cells in several cancer models. We hypothesized that IL-22 regulation would occur at the interface between cancer cells and immune cells. Breast and lung cancer cells of murine and human origin induced IL-22 production from memory CD4 + T cells. In the present study, we found that IL-22 production in humans is dependent on activation of the NLRP3 inflammasome with the subsequent release of IL-1β from both myeloid and T cells. IL-1 receptor signaling via the transcription factors AhR and RORγt in T cells was necessary and sufficient for IL-22 production. In these settings, IL-1 induced IL-22 production from a mixed T helper cell population comprised of Th1, Th17, and Th22 cells, which was abrogated by the addition of anakinra. We confirmed these findings in vitro and in vivo in two murine tumor models, in primary human breast and lung cancer cells, and in deposited expression data. Relevant to ongoing clinical trials in breast cancer, we demonstrate here that the IL-1 receptor antagonist anakinra abrogates IL-22 production and reduces tumor growth in a murine breast cancer model. Thus, we describe here a previously unrecognized mechanism by which cancer cells induce IL-22 production from memory CD4 + T cells via activation of the NLRP3 inflammasome and the release of IL-1β to promote tumor growth. These findings may provide the basis for therapeutic interventions that affect IL-22 production by targeting IL-1 activity.
interleukin-22 | interleukin-1 | inflammasome | cancer immunology | anakinra I L-22 is a cytokine with tumor-promoting properties. It enhances tumor-cell proliferation, protects against apoptosis, and mediates the attraction of immunosuppressive immune cells and the release of pro-and antiinflammatory cytokines (1) . IL-22 also promotes neoangiogenesis and epithelial-to-mesenchymal transition, which are hallmarks of cancer (1, 2) . Unlike other cytokines, IL-22 is produced only by immune cells and binds to IL-22 receptor-1 + (IL-22-R1 + ) nonimmune cells (3) . Strong evidence links IL-22 to colon cancer pathogenesis in both inflammatory and genetic colon cancer models (4) (5) (6) . IL-22 drives the progression of hepatocellular carcinoma, potentially via accelerated tumor-cell proliferation (7, 8) . The presence of IL-22-producing cells is linked to a more aggressive phenotype in a variety of cancer entities such as lung, breast, gastric, and skin cancer, indicating a more universal function of IL-22 in cancer progression (9) (10) (11) (12) (13) . The source of IL-22 in these tumor entities varies, including innate immune cells and CD4
+ T cells (1, 14) . In contrast, the mechanisms by which cancer cells or other cell populations within the tumor environment induce IL-22 production remain unaddressed.
Under physiological conditions and in certain inflammatory diseases such as psoriasis, IL-22 is mainly produced by T cells with smaller contributions from other immune populations (15, 16) . IL-22 production is regulated by the transcription factors retinoic acid-related orphan receptor-γ (ROR-γ) and aryl hydrocarbon receptor (AhR) (15) . Different cytokines have been reported to induce IL-22 production, but no data are available on how cancer cells regulate IL-22 production (15) .
We demonstrate that tumor cells can induce IL-22 production directly from immune cells via IL-1. IL-1 induces the production of IL-22 in a memory CD4
+ Th cell population in mice and Significance IL-22 has been identified as a cancer-promoting cytokine, but its regulation in cancer tissue has not been addressed. Using both murine and human models, we demonstrate that cancer cells directly induce IL-22 production. We prove that interleukin-1β induced by inflammasome activation is critical for IL-22 production. IL-1β increased the activity of the IL-22 transcription factors in lineage-committed T cells. We show the existence of IL-22-producing Th1, Th17, and Th22 cells in tumor tissue of patients. Use of the clinically approved IL-1 receptor antagonist anakinra in vivo reduced IL-22 production and reduced tumor growth in a breast cancer model. These data provide the basis for therapeutic interventions, particularly using anakinra, aiming at limiting IL-22 production in patients with cancer.
humans. We show that reducing endogenous IL-1 activity in vivo, by administering anakinra, leads to diminished IL-22 production and subsequently reduced tumor burden in two different tumor models. In mice, dying tumor cells release IL-1α and initiate IL-22 production, but in humans, cancer cells trigger activation of the NLRP3 inflammasome and the release of IL-1β to regulate IL-22 in memory CD4 + T cells. In patients, we found a strong correlation between the expression of IL-22-related genes and inflammasome activation, supporting the in vivo relevance of our findings. Our study unravels a shared mechanism of IL-22 induction across different cancer types. These findings identify IL-1 as a possible target to therapeutically modulate IL-22 production.
Results

IL-22 Production in Splenocytes Is Induced by Soluble Factors
Released by Murine Breast and Lung Cancer Cell Lines. IL-22 is expressed in most cancer tissues studied so far, including breast and lung cancer (9, 10, 17) . To investigate the source and the regulation of IL-22 production in these diseases, we first analyzed two murine syngeneic cancer models, 4T1 breast cancer and Line-1 lung cancer, for the presence of IL-22 + cells by flow cytometry. We detected IL-22
+ cells with mononuclear cell morphology in spleen and tumor tissue in both models ( Fig. 1 A and B) . We hypothesized that these IL-22
+ cells are nontumor cells, e.g., infiltrating immune cells.
IL-22 was induced in splenocytes incubated with cell-free tumor cell-conditioned supernatants ( Fig. 1 C and D) .
Tumor-Derived IL-1α Drives IL-22 Production from Murine Splenocytes. To identify tumor-derived IL-22-inducing factors, we stimulated splenocytes with 4T1 and Line-1 cell supernatants and found 14 cytokines in the supernatants of the stimulated splenocytes (Fig. S1A ). Of these 14 cytokines, IL-1α, IL-6, IL-23, IFN-γ, TNF-α, and G-CSF have been previously described as being involved in IL-22 induction (14, (18) (19) (20) . IL-1β could not be detected. Testing for the effect of exogenously added cytokines detected only IL-1α and, to a lesser extent, IL-23 induced IL-22 from murine splenocytes (Fig. S1B) . IL-1α and IL-23 were found in relevant amounts in both 4T1 and Line-1 cell lysates ( Fig. S1 C and D) and in tumor-cell supernatants ( Fig. S1 E and  F) . Stimulation of splenocytes with recombinant IL-1α and IL-23 alone or in combination dose-dependently mimicked stimulation with tumor-cell supernatants in terms of IL-22 induction (Fig. S1G ). The addition of anti-IL-1α or anti-IL-23 neutralizing antibodies or both reduced IL-22 induction in splenocytes by tumor-cell supernatants ( Fig. 1 E and F) . Similarly, the addition of the IL-1 receptor (IL-1R) antagonist anakinra to tumor supernatants abrogated IL-22 induction in splenocytes (Fig. S1H) . IL-22 induction was dependent upon IL-1R signaling, as stimulation of IL-1R-KO splenocytes with tumor supernatants or recombinant cytokines did not induce IL-22 production ( Fig. 1 G-I ).
Tumor Cells Induce IL-22 Production in Splenocytes via AhR and RORγt Signaling. To further dissect the mechanism of IL-22 induction by tumor cells, we sought to identify the transcription factors involved. Both AhR and RORγt have been described as playing a role in IL-22 production by immune cells under physiological conditions (21, 22) . The addition of the AhR antagonist CH-223191 or the RORγt antagonist SR-2211 to splenocytes during stimulation with 4T1 and Line-1 cell supernatants significantly reduced IL-22 production. IL-22 production was blocked completely when both antagonists were added ( Fig. 2 A and B) . Moreover, treatment of tumorbearing mice with repeated doses of CH-223191 decreased infiltrating IL-22
+ immune cells and the amount of IL-22 in tumor tissue in both the 4T1 and the Line-1 tumor models ( Fig. S2 A and  B) , pointing toward a role for AhR signaling in IL-22 production in vivo as well.
Murine Tumor Cells Induce IL-22 Production from Memory CD4 + T Cells. Based on the literature, T cells are a major source of IL-22 in mice and humans (14) . We hypothesized that, if T cells are the major source of IL-22 in our system, IL-22 production should be conserved in the CD3 + and CD4 + splenocyte fraction while being reduced in the CD3-or CD4-depleted fraction. Purified CD3 + T cells secreted IL-22 in comparable amounts to splenocytes when stimulated with tumor-cell supernatant. In contrast, IL-22 production was significantly lower in the CD3-depleted fraction ( Fig. S2 C and D) . Similarly, purified CD4 + T cells but not CD4-depleted splenocytes produced IL-22 when stimulated with tumor-cell supernatants or with recombinant IL-1α and IL-23 ( Fig. 2 C and D) . To further characterize the source of 
IL-22 within the CD4
+ T cell population, we stimulated CD4 
CD4
+ and consisted of a mixed Th1, Th17, and Th22 cell population (Fig. 2E ). These phenotype findings were supported by analyzing the supernatants for the presence of the respective prototypical cytokines, such as IL-17 and IFN-γ. IFN-γ and IL-17 were cosecreted in high amounts ( Fig.   S2 E and F) . The IFN-γ and IL-17 production of T cells was also IL-1α dependent, as the induction of either cytokine could be abrogated by the IL-1R antagonist anakinra (Fig. S2 G and H) .
In tumor-bearing mice, we could identify both IL-22-producing CD3 + CD4 + and CD3 + CD8 + T cells in tumor tissue ( Fig.  S2 I and J) . When mice were treated with the AhR antagonist, the amount of IL-22 production was reduced in these T cell fractions (Fig. S2K) . CD4 + CD44 + memory T cells were identified as the target population for IL-1α, as IL-22 induction was detected only in this fraction but not in naive CD4
+ T cells or CD4 − cells (Fig. 2F) .
Blocking of IL-1 Signaling Reduces Tumor Progression and Production of IL-22
+ Cells in Vivo. To confirm our in vitro findings and the relevance of the identified pathway for tumor progression, we tested the impact of IL-1 blockade on tumor growth and IL-22 production in vivo. We used both a neutralizing IL-1R antibody and the soluble IL-1R antagonist anakinra. Tumor progression, as evidenced by tumor growth, was reduced when 4T1 tumor-bearing mice were treated with IL-1R antibody (Fig. 2G) . Growth reduction was paralleled by reduced IL-22 production, as analyzed by flow cytometry, confirming the dependence of IL-22 production on IL-1 (Fig. S2L) . Similarly, when we treated mice bearing the E0771 breast cancer model with anakinra, we again found a striking retardation of tumor growth (Fig. 2H ). As seen in the 4T1 model, IL-22 production was again reduced when IL-1 activity was inhibited (Fig. S2M ). These findings highlight the relevance of the IL-1-IL-22 pathway for cancer progression and point toward the potential use of approved IL-1-antagonizing agents such as anakinra for cancer therapy. Based on the observations in mice, we next asked whether the observed induction of IL-22 production in immune cells by breast and lung cancer cells would also occur in human cells. Human peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated with tumor-conditioned supernatants of three human breast cancer (MCF7, CAMA-1, and MDAMB231) and three human lung cancer (A549, HCC827, and H1339) cell lines. Supernatants from both cancer cell types induced IL-22 production in human PBMCs, and this induction was attributable to soluble factors ( Fig. 3 A and B) . In contrast, stimulation of PBMCs with non-tumor-cell supernatant (from HEK293 cells) failed to lead to IL-22 production (Fig. S3A) .
Tumor Cell-Derived IL-1α and Tumor Cell-Induced IL-1β Lead to IL-22 Production in Human PBMCs in an AhR-and RORγt-Dependent Manner.
To further investigate the mechanism of IL-22 induction by cancer cells in human PBMCs, we added the IL-1R antagonist anakinra to the conditioned supernatants of breast and lung cancer cell lines. Anakinra blocked IL-22 induction in PBMCs stimulated with breast and lung cancer cell supernatants in a similar fashion (Fig. 3  C and D) . In tumor-cell supernatants, we found IL-1α (but not IL-1β) in two of the human cell lines, H1339 and MDAMB231 cells (Fig. S3 B and C) . IL-1α was also induced after stimulation with supernatants except for the H1339 supernatant (Fig. S3 B and C) . Incubation of human PBMCs with any of the tumor-cell supernatants tested induced IL-1β production (Fig. S3 D and E) . For all human cell lines analyzed, IL-1β was the main driver of IL-22 induction in PMBCs, as anti-IL-1β but not anti-IL-1α antibodies antagonized IL-22 induction in HCC827, H1339, CAMA-1, and MDAMB231 cell lines (Fig. S3 F-I ). At the transcription factor level, IL-22 induction was dependent on both AhR and RORγt signaling in PBMCs (Fig. 3 E and F and Fig. S4 A and B) . Mice were treated with 1 mg anakinra or PBS i. p. every day beginning on day 0. In A-F error bars represent the SEM, and P values by two-sided Student's t test are shown. In G and H, statistical significance was analyzed by two-way ANOVA with correction for multiple testing; n.d., not detectable; n.s., not significant; rec., recombinant.
detected IL-1β production by myeloid cells and to a lesser extent by CD4
+ T cells after stimulation with tumor supernatants (Fig.  S4C) . To further dissect the mechanism responsible for IL-1β production, we used the specific NLRP3 inhibitor, the cytokine release inhibitory drug CRID3, and the pan-caspase inhibitor Z-Vad. The addition of CRID3 and Z-Vad abolished IL-22 production in a concentration-dependent manner (Fig. 3 G and H and Fig. S5 A and B) , suggesting the involvement of inflammasome activation by the tumor cells.
To identify the cell type responsible for IL-22 production upon the addition of tumor cell-conditioned supernatants to PBMCs, we analyzed their phenotype by flow cytometry. Most IL-22 + cells were CD3 + CD4 + and consisted of a mixed Th1, Th17, and Th22 cell population (Figs. S4 D and E and S5 C and D) . We purified and stimulated CD4 + T cells with lung and breast cancer cell supernatants. Secretion of IL-22 by CD4 + T cells was comparable to that from whole PBMCs, but IL-22 production was almost absent in the CD4-depleted fraction (Figs. S4 F and G and S5 E and F). Similarly, stimulation of CD4 + T cells, but not of CD4-depleted PBMCs, with recombinant IL-1α or IL-1β led to IL-22 production (Fig. S4H) , indicating that the CD4 + T cell fraction is the target of IL-1 and the source of IL-22 production. To further characterize the T cell population involved, we isolated naive and memory CD4 + T cells. We found that isolated memory CD4 + T cells were proficient IL-22 producers in our settings. Naive CD4 + T cells did not produce IL-22, whereas the naive CD4 + T cell-depleted fraction retained their ability to induce IL-22 (Fig.  S5G) . IL-22 induction by A549 tumor supernatant was still seen in the purified CD4 + T cell population and was dependent on the activation of the NLRP3 inflammasome (Fig. S5H) .
This mixed phenotype of different Th lineages was further confirmed by analysis of supernatants after stimulation of PBMCs with tumor-conditioned supernatants. IFN-γ and IL-17 cosecretion was found in all cultures analyzed, supporting the presence of Th1, Th17, and Th22 cells in the culture (Fig. S6 A-D) . The production of IL-22 appears to be dependent on these subpopulations, as addition of the IL-1R antagonist anakinra to the PBMCs incubated with tumor-cell supernatants blocked the induction of both IFN-γ and IL-17 in addition to blocking IL-22 production (Fig. S6 E-H) . These results indicate that tumor cells can induce cytokine production from Th1, Th17, and Th22 cells in an IL-1R-dependent manner via activation of the NLRP3 inflammasome. + cells in lung cancer samples, the main fraction, accounting for 50% of these cells, was of a Th1 phenotype, followed by Th22 and Th17 phenotypes (14% and 6%, respectively) (Fig. S7C) . Expression of IL-22 in lung cancer tissue was confirmed in protein lysates of the same tumor samples (Fig. S7D) . IL-22 was found at higher levels in lung cancer than in matched nontumor tissue from the same patient (Fig. S7 B and  D) . To corroborate the link between IL-22 production and IL-1, we next correlated protein levels of both cytokines. We found a significant correlation between IL-22 and IL-1α, compatible with the dependence of IL-22 production on the presence IL-1 in tumor tissue from patients (Fig. S7E) . Expression of IL-22 could also be confirmed in breast cancer tissue (n = 7) (Fig. S8D) . There, in line with our in vitro findings, we could confirm a predominant expression of IL-22 by CD4 + T cells consisting of Th1 (41%), Th17 (9%), and Th22 (23%) cells (Fig. S8C) .
IL-22 Expression and Inflammasome Activation Correlate in Human
Lung and Breast Adenocarcinoma. To further link inflammasome activation with IL-22 production, we next analyzed expression data from two clinical cohorts of patients with lung (n = 80) or breast (n = 45) cancer (23, 24) . Thirty-three transcripts related to the IL-22 pathway were arbitrarily selected (Fig. S9A) . Lung and breast samples were hierarchically clustered to these 33 transcripts, and transcripts that clustered together and were closely related with IL22 were further analyzed by hierarchical clustering to identify their power to discriminate normal from cancer tissues (Fig. S9 B  and D) . The inflammasome-related genes enabled differentiation between cancer and noncancer tissue in lung cancer but not in breast cancer (Fig. S9 B and D) . When lung and breast cancer tissues were analyzed separately, excluding normal tissues, we found a clear correlation between inflammasome-and IL-22-related genes, further underscoring the relationship between IL-22 production and inflammasome activation (Fig. S9 C and E) .
Discussion
Our study describes a mechanism by which cancer cells induce IL-22 production from CD4 + T cells in mice and in humans in an AhR-and RORγt-dependent manner. In mice, IL-22 production is dependent on IL-1α release by cancer cells. IL-22 content in tumor tissue and tumor growth are reduced when IL-1 is neutralized in two different breast cancer models. Human cancer cells induce IL-22 through the activation of the NLRP3 inflammasome, resulting in IL-1β release. In patients, the degree of inflammasome activation correlates with IL-22 content in human breast and lung cancer samples.
A role for IL-22 in cancer development and progression has been recognized in several epithelial cancers, including breast and lung cancer (1, 9) . When released by immune cells, IL-22 can act on cancer cells to promote tumor growth, aggressiveness, and treatment resistance (1, 25) . However, no study has yet investigated the mechanism by which IL-22 production is induced or which immune cells are able to produce IL-22 in the tumor environment. Our findings provide evidence that cancer cells affect memory CD4
+ T cells to express and release IL-22 in an IL-1-dependent manner and that this shared mechanism promotes tumor growth.
IL-1α and IL-1β are two cytokines with shared signaling via IL-1R but with a different biology (26) . IL-1β is a driver of IL-22 production by immune cells and by Th17 cells in particular (27) (28) (29) . In our study, IL-1R signaling was central to cancer celldriven IL-22 production, but the mediating IL-1 family members differed between species. In mice, IL-1α was the main inducer of IL-22 production and was detected in the supernatants and protein lysates of cancer cells. IL-1α is mostly cell-associated in viable cells but may be released from dying tumor cells (30, 31) . In addition, IL-1α can induce its own release from immune cells, further enhancing its effects on IL-1R + cells, as previously described (32) . IL-1 is detectable in human breast, colon, lung, and head and neck cancers and in melanoma. Its detection is typically associated with a worse prognosis (17) . In line with these findings, inhibition of endogenous IL-1 activity by administering anakinra reduces both the extent of metastasis and tumor burden (18) . Comparable effects are also known for the NLRP3 inflammasome (33) . Our findings link endogenous IL-1 activity to IL-22 induction in two different breast cancer models.
In contrast to the murine system, in human cancer cell lines cocultured with PBMCs, IL-1β is the main inducer of IL-22 and is induced in PBMCs. The specific NLRP3 inhibitor CRID3 abolished both IL-1β and IL-22 production in whole PBMCs and in purified CD4
+ memory T cells, indicating that NLRP3 is required for inflammasome activation. A mechanism of NLRP3 inflammasome activation could be the release of IL-1α precursor or uric acid from dying tumor cells. These act on immune cells and activate the NLPR3 inflammasome (34) (35) (36) (37) . Release of ATP from tumor cells or tumor cell-derived nucleic acids may also result in NLRP3 activation and IL-1β release (38, 39) .
We have identified memory CD4 + T cells as a primary target of the released IL-1β for IL-22 induction. Mechanistically, IL-1β could activate a preexisting pool of Th1, Th17, and Th22 cells for IL-22 production (40) . Alternatively, there is evidence that IL-1β can drive the differentiation of memory T cells to these Th cell lineages (41, 42) .
The transcription factor RORγt is required for Th17 and Th22 polarization, and the transcription factor AhR is additionally required for Th22 differentiation in mice (43) (44) (45) . Similarly, RORγt and AhR are involved in IL-22 production (46, 47) . Our findings show that both transcription factors are also required for IL-22 production in the setting of cancer cellinduced IL-22 production.
The cellular source of IL-22 in the tumor microenvironment varies according to the tumor entity and the species studied (1, 5) . In the present study, we demonstrate that murine and human breast and lung cancer cells induce IL-22 production from a mixed population of Th1, Th17, and Th22 cells in an IL-1-dependent manner. Our findings are compatible with studies that have identified Th1 and Th17 cells in breast and lung cancer (48) (49) (50) . The presence of these cells has been reported to correlate with worsened clinical outcomes (49, 51, 52) . We could identify a positive correlation between inflammasome activation and IL-22 production in tumor tissue specimens from two patient cohorts with lung and breast cancer, respectively.
In summary, our study describes a previously unrecognized mechanism by which cancer cells can induce IL-22 in T cells. It provides a link between the widely described expression and function of IL-22 in cancer and its cellular source (Fig. S10) . On another line, we provide pathophysiological insights into the effect of clinical IL-1 blockade recently described in lung cancer (53) . The availability of clinically approved IL-1-antagonizing agents such anakinra and its favorable safety profile place clinical testing for tumor indications within reach. Clinical trials with anakinra in patients with breast cancer are under way, so far showing promising preliminary data (54) . Our findings add to the rationale for developing therapeutic interventions targeting the IL-1-IL-22 axis.
Materials and Methods
Mice. All animal experiments were approved by the local regulatory agency (Regierung von Oberbayern) or by the Veterinary Administration of the Prefecture of Western Greece (protocol approval no. 118018/578) and adhered to the NIH guidelines for the care and use of laboratory animals. Cytokine Secretion Assays. Splenocytes, purified T cells, and PBMCs were cultivated as indicated (see SI Materials and Methods and figure legends for details).
Flow Cytometry. Flow cytometry was performed according to standard protocols as indicated (see SI Materials and Methods for details).
Statistics. FlowJo V9.2 software (TreeStar) was used for analysis of FACS datasets. Statistics were calculated with GraphPad Prism software 5.0. Differences between experimental conditions were analyzed using the unpaired two-tailed Student's t test. The Mann-Whitney U test was used to compare data points from individual mice. A paired two-tailed Student's t test was used when comparing experimental conditions for individual human donors. Statistical significance was analyzed by two-way ANOVA with correction for multiple testing in case of tumor growth curves. P values < 0.05 were considered significant.
Data Availability. All data supporting this paper are attached. Raw data and reagents will be made available upon reasonable request to the authors.
